Stock NVO NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Company Novo Nordisk A/S Nyse

Equities

NVO

US6701002056

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 11:39:19 2024-05-03 EDT 		5-day change 1st Jan Change
122.8 USD -1.00% Intraday chart for Novo Nordisk A/S -3.13% +18.79%
05:34pm Novo Nordisk: share price falls, analyst adjusts target CF
05:29pm Catalent, Novo Nordisk Antitrust Review Extended by FTC MT

Business Summary

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- diabetes and obesity treatment products (92.6%);

- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Number of employees: 63,845

Sales per Business

DKK in Million2022Weight2023Weight Delta
Diabetes and Obesity Care
92.6 %
156,412 88.4 % 215,098 92.6 % +37.52%
Rare Disease
7.4 %
20,542 11.6 % 17,163 7.4 % -16.45%

Sales per region

DKK in Million2022Weight2023Weight Delta
United States
54.9 %
84,656 47.8 % 127,534 54.9 % +50.65%
EMEA
21.9 %
44,236 25.0 % 50,867 21.9 % +14.99%
Rest of the World
12.1 %
25,402 14.4 % 28,078 12.1 % +10.53%
China
7.2 %
16,209 9.2 % 16,687 7.2 % +2.95%
Canada
3.9 %
6,451 3.6 % 9,095 3.9 % +40.99%

Managers

Managers TitleAgeSince
Lars Fruergaard Jorgensen CEO
 Chief Executive Officer 58 90-12-31
Karsten Munk Knudsen DFI
 Director of Finance/CFO 53 98-12-31
Stephen Gough CTO
 Chief Tech/Sci/R&D Officer - 15-09-30
Marcus Schindler CTO
 Chief Tech/Sci/R&D Officer 57 17-12-31
Maziar Mike Doustdar COO
 Chief Operating Officer 54 91-12-31
Henrik Ehlers Wulff CTO
 Chief Tech/Sci/R&D Officer 54 98-12-31
Daniel Bohsen IRC
 Investor Relations Contact - 20-02-29
Tania Sabroe HRO
 Human Resources Officer 47 06-12-31
Irina Ivanischeva LAW
 General Counsel - -
Sergey Manelis PRN
 Corporate Officer/Principal - 20-07-12

Members of the board

Members of the board TitleAgeSince
Sylvie Grégoire BRD
 Director/Board Member 63 15-03-18
Helge Lund CHM
 Chairman 61 17-03-22
Martin MacKay BRD
 Director/Board Member 68 18-02-28
Laurence Debroux BRD
 Director/Board Member 54 19-03-20
Kasim Kutay BRD
 Director/Board Member 59 17-03-22
Andreas Fibig BRD
 Director/Board Member 62 18-02-28
Henrik Poulsen BRD
 Director/Board Member 57 21-03-24
Liselotte Hyveled BRD
 Director/Board Member 58 91-12-31
Mette Bøjer Jensen BRD
 Director/Board Member 49 18-03-21
Thomas Rantzau BRD
 Director/Board Member 52 18-03-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,075,000,000 0 0 70.17 %
Stock B 1 3,390,128,000 3,133,044,823 ( 92.42 %) 51,700,000 ( 1.525 %)

Shareholders

NameEquities%Valuation
ATP Fondsmaeglerselskab A/S
8.698 %
298,789,780 8.698 % 38 200 M $
Novo Holdings A/S (Investment Company)
5.536 %
190,183,000 5.536 % 24 315 M $
NOVO NORDISK A/S
1.417 %
48,674,207 1.417 % 6 223 M $
Pensionskassernes Administration A/S
0.7345 %
25,229,760 0.7345 % 3 226 M $
PFA Kapitalforvaltning Fondsmæglerselskab A/S
0.6898 %
23,696,970 0.6898 % 3 030 M $
Amundi Asset Management SA (Investment Management)
0.6168 %
21,188,231 0.6168 % 2 709 M $
MP Investment Management A/S
0.5844 %
20,075,914 0.5844 % 2 567 M $
Swedbank Robur Fonder AB
0.4784 %
16,434,239 0.4784 % 2 101 M $
Capital International KK
0.2947 %
10,123,000 0.2947 % 1 294 M $
State Street Global Advisors Ltd.
0.2867 %
9,848,006 0.2867 % 1 259 M $
NameEquities%Valuation
Novo Holdings A/S (Investment Company)
100.00 %
1,074,872,000 100.00 % 137 B $
ANIMA Sgr SpA
0.0129 %
138,860 0.0129 % 18 M $
Fineco Asset Management DAC
0.009413 %
101,181 0.009413 % 13 M $
NS Partners SA
0.006408 %
68,876 0.006408 % 9 M $
Kieger AG
0.002940 %
31,596 0.002940 % 4 M $
Mercer Global Investments Europe Ltd.
0.002487 %
26,732 0.002487 % 3 M $
OLZ AG
0.001913 %
20,557 0.001913 % 3 M $
Union Bancaire Privée, UBP SA
0.001241 %
13,340 0.001241 % 2 M $
Swissinvest Institut für Angewandte Finanzmarktanalysen GmbH
0.000698 %
7,500 0.000698 % 958 880 $
DJE Kapital AG
0.000616 %
6,616 0.000616 % 845 860 $
NameEquities%Valuation
Jennison Associates LLC
0.6558 %
22,527,772 0.6558 % 2 893 M $
Fisher Asset Management LLC
0.4113 %
14,129,598 0.4113 % 1 814 M $
Merrill Lynch International
0.4066 %
13,968,876 0.4066 % 1 794 M $
Renaissance Technologies LLC
0.4032 %
13,849,335 0.4032 % 1 778 M $
Fidelity Management & Research Co. LLC
0.3686 %
12,663,225 0.3686 % 1 626 M $
Fayez Sarofim & Co.
0.3439 %
11,814,051 0.3439 % 1 517 M $
Eaton Vance Management
0.3090 %
10,614,811 0.3090 % 1 363 M $
Loomis, Sayles & Co. LP
0.2621 %
9,003,325 0.2621 % 1 156 M $
Folketrygdfondet
0.2549 %
8,756,034 0.2549 % 1 124 M $
Royal Trust Corp. of Canada
0.2326 %
7,988,697 0.2326 % 1 026 M $

Holdings

NameEquities%Valuation
NOVO NORDISK A/S
1.42%
 48,674,207 1.42% 6,223,028,030 $
NNIT A/S
17.50%
 4,375,000 17.50% 68,672,756 $
INNATE PHARMA
12.14%
 9,817,546 12.14% 23,167,445 $

Company contact information

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com
address Novo Nordisk A/S(NVO)

Group companies

NameCategory and Sector
NNE A/S
Logo NNE A/S

NNE A/S

Engineering & ConstructionIndustrial Services

Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The private company is based in Soborg, Denmark.

Engineering & Construction
Novo Nordisk Region Europe A/S
Logo Novo Nordisk Region Europe A/S

Novo Nordisk Region Europe A/S

Financial ConglomeratesFinance

Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark.

Financial Conglomerates
Novo Nordisk Health Care AG
Logo Novo Nordisk Health Care AG

Novo Nordisk Health Care AG

Pharmaceuticals: MajorHealth Technology

Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland.

Pharmaceuticals: Major
Novo Nordisk India Pvt Ltd.
Logo Novo Nordisk India Pvt Ltd.

Novo Nordisk India Pvt Ltd.

Medical/Nursing ServicesHealth Services

Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The private company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases.

Medical/Nursing Services
World Diabetes Foundation
Investment Trusts/Mutual Funds
Velfærdsfonden for Novo Nordisk A/S
Investment Trusts/Mutual Funds
Novo Nordisk Finance (Netherlands) BV
Finance/Rental/Leasing

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
873.1 DKK
Average target price
906.2 DKK
Spread / Average Target
+3.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.90% 681B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.08% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.24% 325B
ABBVIE INC. Stock AbbVie Inc.
+4.74% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.42% 235B
NOVARTIS AG Stock Novartis AG
+3.58% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.25% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.95% 157B
AMGEN INC. Stock Amgen Inc.
+8.94% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. NVO Stock
  5. Company Novo Nordisk A/S